Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 8.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 466,028 shares of the company's stock after purchasing an additional 37,079 shares during the quarter. Assenagon Asset Management S.A. owned about 0.55% of Syndax Pharmaceuticals worth $8,971,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sei Investments Co. increased its stake in Syndax Pharmaceuticals by 2.5% during the 1st quarter. Sei Investments Co. now owns 40,463 shares of the company's stock worth $963,000 after buying an additional 991 shares during the period. California State Teachers Retirement System increased its position in shares of Syndax Pharmaceuticals by 1.5% during the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company's stock worth $1,822,000 after acquiring an additional 1,150 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at $27,000. Ameritas Investment Partners Inc. boosted its holdings in Syndax Pharmaceuticals by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company's stock valued at $187,000 after purchasing an additional 1,312 shares during the period. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in Syndax Pharmaceuticals by 28.4% in the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company's stock valued at $171,000 after purchasing an additional 1,587 shares during the period.

Syndax Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ SNDX traded down $0.13 during trading hours on Tuesday, reaching $19.08. The stock had a trading volume of 473,068 shares, compared to its average volume of 1,053,682. The firm has a 50-day moving average of $19.23 and a 200-day moving average of $20.40. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -5.97 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $12.45 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.11. The business had revenue of $3.50 million for the quarter. During the same quarter in the previous year, the business posted ($0.64) EPS. The company's revenue was up 3499999990.0% on a year-over-year basis. On average, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current year.

Wall Street Analysts Forecast Growth

SNDX has been the topic of a number of analyst reports. Citigroup increased their price target on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Stifel Nicolaus raised their target price on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a "buy" rating in a report on Monday, October 14th. JPMorgan Chase & Co. decreased their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Barclays increased their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday, August 15th. Finally, HC Wainwright raised their price objective on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a "buy" rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $35.90.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).